| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1086: Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence |
|
Medicine details |
|
| Medicine name | ribociclib succinate (Kisqali®) |
| Formulation | 200 mg film-coated tablets |
| Reference number | 5132 |
| Indication | For adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/06/2025 |
| NICE guidance | |